Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus

Clinical Endocrinology

Volumn 76, Issue 6, 2012, Pages 810-815

  Wang, Chun ^a   Lv, Lifang ^a   Yang, Yanzhi ^a   Chen, Dawei ^a   Liu, Guanjian ^a   Chen, Lihong ^a   Song, Yuanxia ^a   He, Liping ^a   Li, Xiujun ^a   Tian, Haoming ^a   Jia, Weiping ^b   Ran, Xingwu ^a  

^a SICHUAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BLOOD GLUCOSE MONITORING; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LARGEST AMPLITUDE OF GLYCEMIC EXCURSION; MAJOR CLINICAL STUDY; MALE; MEAN AMPLITUDE OF GLYCEMIC EXCURSION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL GLUCOSE EXCURSION; PRIORITY JOURNAL;

ADULT; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 84860118180     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04205.x     Document Type: Article

References (27)

1. 1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes, 44, 968-983.
2. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352, 854-865.
3. Brownlee, M., &, Hirsch, I.B., (2006) Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA, 295, 1707-1708.
4. Cryer, P.E., (2002) Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia, 45, 937-948.
5. The Diabetes Control and Complications Trial Research Group (1997) Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes, 46, 271-286.
6. McCall, A.L., &, Kovatchev, B.P., (2009) The median is not the only message: a clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus. Journal of Diabetes Science and Technology, 3, 3-11.
7. Klonoff, D.C., (2005) Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care, 28, 1231-1239.
8. Kilpatrick, E.S., Rigby, A.S., &, Atkin, S.L., (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care, 29, 1486-1490.
9. Cemeroglu, A.P., Stone, R., Kleis, L., et al. (2010) Use of a real-time continuous glucose monitoring system in children and young adults on insulin pump therapy: patients' and caregivers' perception of benefit. Pediatric Diabetes, 11, 182-187.
10. Ryan, M.T., Savarese, V.W., Hipszer, B., et al. (2009) Continuous glucose monitor shows potential for early hypoglycemia detection in hospitalized patients. Diabetes Technology & Therapeutics, 11, 745-747.
11. Franzese, A., Valerio, G., Buono, P., et al. (2008) Continuous glucose monitoring system in the screening of early glucose derangements in children and adolescents with cystic fibrosis. Journal of Pediatric Endocrinology and Metabolism, 21, 109-116.
12. Bialasiewicz, P., Pawlowski, M., Nowak, D., et al. (2009) Decreasing concentration of interstitial glucose in REM sleep in subjects with normal glucose tolerance. Diabetic Medicine, 26, 339-344.
13. American Diabetes Association (2009) Standards of medical care in diabetes-2009. Diabetes Care, 32 (Suppl.), s13-s61.
14. Koschinsky, T., &, Heinemann, L., (2001) Sensors for glucose monitoring: technical and clinical aspects. Diabetes/Metabolism Research and Reviews, 17, 113-123.
15. Service, F., Molnar, G.D., Rosevear, W., et al. (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes, 19, 644-655.
16. Molnar, G.D., Taylor, W.F., &, Ho, M.M., (1972) Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia, 8, 342-348.
17. Service, F.J., &, Nelson, R.L., (1980) Characteristics of glycemic stability. Diabetes Care, 3, 58-62.
18. He, L.P., Wang, C., Zhong, L., et al. (2009) Glycemic excursions in people with normal glucose tolerance in Chengdu. Sichuan Da Xue Xue Bao Yi Xue Ban, 40, 704-707.
19. Zhou, J., Li, H., Ran, X., et al. (2009) Reference values for continuous glucose monitoring in Chinese subjects. Diabetes Care, 32, 1188-1193.
20. Mcgowan, K., Thomas, W., &, Moran, A., (2002) Spurious reporting of nocturnal hypoglycemia by cgms in patients with tightly controlled type 1 diabetes. Diabetes Care, 25, 1499-1503.
21. Kovatchev, B.P., Gonder- Frederick, L.A., Cox, D.J., et al. (2004) Evaluating the accuracy of continuous glucose-monitoring sensors: continuous glucose-error grid analysis illustrated by TheraSense Freestyle Navigator data. Diabetes Care, 27, 1922-1928.
22. Borg, R., Kuenen, J.C., Carstensen, B., et al. (2010) Real-life glycaemic profiles in non-diabetic individuals with low fasting glucose and normal HbA1c: the A1C-Derived Average Glucose (ADAG) study. Diabetologia, 53, 1608-1611.
23. Guettier, J.M., &, Gorden, P., (2006) Hypoglycemia. Endocrinology and Metabolism Clinics of North America, 35, 753-766, viii-ix.
24. Cryer, P., (2008) Glucose homeostasis and hypoglycemia. In:, H. Kronenberg, S. Melmed, K. Polonsky, P. Larsen, eds. Williams Textbook of Endocrinology, 11th edn. Saunders, an imprint of Elsevier, Inc., Philadelphia, PA, 1503-1533.
25. Monnier, L., Colette, C., &, Owens, D.R., (2008) Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? Journal of Diabetes Science and Technology, 2, 1094-1100.
26. Ceriello, A., (2003) The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia, 46 (Suppl. 1), M9-M16.
27. Chiasson, J.L., Josse, R.G., Gomis, R., et al. (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA, 290, 486-494.